JP2023549323A5 - - Google Patents
Info
- Publication number
- JP2023549323A5 JP2023549323A5 JP2023525999A JP2023525999A JP2023549323A5 JP 2023549323 A5 JP2023549323 A5 JP 2023549323A5 JP 2023525999 A JP2023525999 A JP 2023525999A JP 2023525999 A JP2023525999 A JP 2023525999A JP 2023549323 A5 JP2023549323 A5 JP 2023549323A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acid
- renal
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0152247 | 2020-11-13 | ||
| KR20200152247 | 2020-11-13 | ||
| PCT/KR2021/016630 WO2022103221A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549323A JP2023549323A (ja) | 2023-11-24 |
| JP2023549323A5 true JP2023549323A5 (enExample) | 2024-11-25 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525999A Pending JP2023549323A (ja) | 2020-11-13 | 2021-11-15 | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (enExample) |
| EP (1) | EP4245311A4 (enExample) |
| JP (1) | JP2023549323A (enExample) |
| KR (1) | KR20220065719A (enExample) |
| CN (1) | CN116419760A (enExample) |
| AU (1) | AU2021378707A1 (enExample) |
| CA (1) | CA3196258A1 (enExample) |
| CO (1) | CO2023006437A2 (enExample) |
| IL (1) | IL302858A (enExample) |
| MX (1) | MX2023005580A (enExample) |
| WO (1) | WO2022103221A1 (enExample) |
| ZA (1) | ZA202304534B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250040515A (ko) * | 2023-09-14 | 2025-03-24 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 신규한 동결 건조 제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| RS59830B1 (sr) * | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CA3048151A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| EP3650539A4 (en) * | 2017-07-07 | 2021-08-18 | Hanmi Pharm. Co., Ltd. | NEW THERAPEUTIC ENZYMFUSION PROTEIN AND ITS USAGE |
| FR3069340A1 (fr) * | 2017-07-21 | 2019-01-25 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| BR112020012346A2 (pt) * | 2017-12-22 | 2020-11-24 | Hanmi Pharm. Co., Ltd. | proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma |
-
2021
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2280083T3 (es) | Composiciones de proteinas de fusion ob y metodos. | |
| EP3528833B1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| KR102853359B1 (ko) | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 | |
| JP5524049B2 (ja) | 目的ペプチドの血漿中半減期延長作用を有するペプチド | |
| KR101893010B1 (ko) | ＴＮＦα를 저해하는 안정한 가용성 항체 | |
| CN101553243B (zh) | 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体 | |
| JP7303629B2 (ja) | 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物 | |
| RU2005115477A (ru) | Нейтрализующие антитела против gdf-8 и их применение | |
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2022081634A (ja) | プロテアーゼで切断可能なリンカーを有するペプチド構築体 | |
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| CN109796534B (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JP2025504625A5 (enExample) | ||
| JP2020526497A5 (enExample) | ||
| JPH08504210A (ja) | 結合生物活性ペプチドを使用した敗血症性ショックの治療 | |
| CA3251039A1 (en) | NEW CD200 FUSION PROTEINS | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| WO2025147483A1 (en) | Methods of using activin receptor type ii chimeras | |
| JP2023549322A5 (enExample) | ||
| WO2024125445A1 (zh) | 一种靶向TNF-α与IL-17A的双特异性融合蛋白及其用途 | |
| JP5004408B2 (ja) | 抗ｈｉｖ組成物、その製造方法及び医薬 | |
| JP2022513626A5 (enExample) | ||
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 |